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Key messages
 ► This study provides detailed information on how 
the first set of patient-centred outcomes in patients 
with a diagnosis of pulmonary sarcoidosis was 
developed.
 ► The international process resulted in a consen-
sus-driven recommended set.
 ► This standard setallows meaningful comparisons of 
outcomes and practices at different hospitals which 
can enable sharing of ‘best practices’ to improve the 
care for pulmonary sarcoidosis globally.
AbstrAct
Introduction Routine and international comparison of 
clinical outcomes enabling identification of best practices 
for patients with pulmonary sarcoidosis is lacking. The aim 
of this study was to develop a standard set of outcome 
measures for pulmonary sarcoidosis, using the value-
based healthcare principles.
Methods Six expert clinics for interstitial lung diseases in 
four countries participated in a consensus-driven RAND-
modified Delphi study. A mixed-method approach was 
applied for the identification of an outcome measures 
set and initial conditions for patients with pulmonary 
sarcoidosis. The expert team consisted of multidisciplinary 
professionals (n=14) from Cleveland Clinic, Cincinnati MC, 
Erasmus MC, Leuven UZ, Royal Brompton and St. Antonius 
Hospital. During a ranking process, participants were 
instructed to rank variables on a scale from 1 to 10 based 
on whether it has (1) impact of the outcome on quality of 
life, (2) impact of quality of care on the outcome and (3) the 
number of patients negatively affected by the outcome.
results An outcome measures set was defined consisting 
of seven outcome measures: mortality, pulmonary function, 
soluble interleukin-2 receptor change as an activity 
biomarker, weight gain, quality of life, osteoporosis and 
clinical outcome status.
Discussion Collecting outcomes in pulmonary sarcoidosis 
internationally and the use of a broadly accepted set can 
enable international comparison. Differences in outcomes 
can potentially be used as a starting point for quality 
improvement initiatives.
IntroDuctIon
Sarcoidosis is a chronic systemic disease 
of unknown aetiology, characterised histo-
logically by granulomatous inflammation. 
Existing treatment options include either 
no medication or a mix of first-line, second-
line and third-line medication with trade-offs 
between treating inflammation and quality 
of life (QoL).1 A chronic disease course 
requires long-term treatment with corticos-
teroids, cytotoxics and other agents that can 
have a serious impact on the quality of life.2 
Significant grey areas exist in approaches 
to treatment and thus how care is delivered 
across different countries and centres.3 Little 
knowledge is available regarding outcomes of 
delivered care in relation to the various treat-
ment options. Therefore, there is a need for 
standardisation of core outcomes to ensure 
high-value care delivery for all patients with 
sarcoidosis globally.
Patients suffering from chronic diseases 
have persistent needs and therefore need 
ongoing healthcare. Accordingly, patients 
with complex chronic conditions, such as 
sarcoidosis, are also the costliest patients, and 
costs increase with the number of chronic 
conditions.4 In patients with sarcoidosis, it 
has been confirmed they have higher rates 
of comorbidity and complexity compared 
with a matched control group (matched for 
age and gender). Furthermore, it was found 
that the main comorbidities were pulmonary, 
liver, autoimmune and neoplastic disease 
in patients with sarcoidosis compared with 
controls.5 It was estimated that commer-
cial payers incurred US$19 714 annually 
on healthcare costs spent per patient with 
sarcoidosis in the USA, with outpatient visits 
and inpatient admissions as the two main cost 
drivers.6
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Globally, healthcare providers are driven by similar 
goals: to improve patient experiences and healthcare 
outcomes, to become more efficient and to reduce the 
costs as well as to innovate the way care is provided. As 
addressed by Porter, value-based healthcare (VBHC) 
could be a guiding principle in achieving these multiple 
goals.7 8 In particular, transparently sharing treatment 
outcomes of routine clinical care can help hospitals to 
learn from each other and improve patient value, defined 
as outcomes over costs.
Sarcoidosis often affects young and middle-aged adults. 
Patients suffer from a broad range of non-specific symp-
toms, with high variability in the degree of inflammation 
as well as organs affected. In more than 90% of the cases, 
sarcoidosis affects the lungs.2 9–11 Spontaneous remissions 
occur in approximately two-thirds of the patients, but the 
disease course is chronic in 10%–30% of the patients.9 
Incidence and prevalence rates reported in the literature 
are highly variable. The prevalence varies over geograph-
ical regions as well as ethnic groups, with the highest 
sarcoidosis prevalence reported in the Nordic countries 
and in individuals of African descent.9 12 For this study, we 
aimed to specifically develop a standard set of outcome 
measures for patients with pulmonary sarcoidosis.
In order to optimise treatment to the individual patient 
with sarcoidosis, the availability of centre-level outcome 
data has the potential to provide important advantages 
for quality improvement efforts. Hospitals can learn 
from variations in the outcomes of care, as demonstrated 
in cystic fibrosis centres.13 Globally, there is a broader 
interest in studying the within-hospital as well as the 
between-hospital variation in various medical condi-
tions.14 15 Without having defined a set of meaningful 
and internationally accepted measures, it is not possible 
to compare results and identify best practices.
The primary objective of this study was to define a 
consensus-driven, patient-centred outcome set enabling 
international comparison of clinical outcomes of patients 
with pulmonary sarcoidosis, including a set of initial 
conditions needed for case-mix corrections.
MethoDs
study structure and design
A project group supervised the selection process of the 
outcome set. Initial identification of potentially relevant 
outcomes was established by an international working 
group with pulmonologists from six recognised expert 
clinics in four countries: Cleveland Clinic (USA), Cincin-
nati MC (USA), Erasmus MC (the Netherlands), Leuven 
UZ (Belgium), the Royal Brompton (UK) and the St. 
Antonius Hospital (the Netherlands).
An international team of experts (n=14) from the six 
expert clinics convened through webinars and a face-to-
face session to reach consensus on the set of outcome 
measures and case-mix variables using a structured 
consensus-driven RAND-modified Delphi method (see 
online supplementary material appendix 1 for the full 
list of experts).16 17 The selection process was conducted 
between January 2014 and January 2015.
Patient population and condition scope
The outcome set was designed for patients with pulmonary 
sarcoidosis. The working group acknowledged sarcoidosis 
as a very heterogeneous population, with the possibility of 
single extrapulmonary organ involvement, such as ocular 
sarcoidosis. However, as the lungs are involved in 90% of 
patients with sarcoidosis,2 18 only patients with pulmonary 
involvement (including isolated hilar/mediastinal) were 
included in the dataset. The definition for sarcoidosis 
for this patient group was in line with the international 
accepted statement on sarcoidosis9: (1) the patient has 
to be diagnosed with pulmonary sarcoidosis and (2) the 
diagnosis is performed by a pulmonologist.
Development of the standard set
In order to develop the standard set, a systematic 
approach was employed, identifying outcomes based on 
the three-tier principles of Porter: tier 1, health status 
(survival and degree of health); tier 2, recovery process 
(time to recovery, disutility of care); and tier 3, sustain-
ability of health (ie, sustainability of health or recovery 
and long-term consequences of therapy).8
The development of the set was structured in three 
main phases. First, as introduced by Kaplan and Porter,8 19 
the care delivery value chain for pulmonary sarcoidosis 
was described. This allowed to map the total care delivery 
of the diverse activities. Second, a literature review was 
carried out by the working group guiding the identi-
fication of important outcomes and the related initial 
conditions. Third, the working group identified potential 
outcomes, applying the process for standard set devel-
opment introduced by Meetbaar Beter (in 2017, Meetbaar 
Beter merged with the Netherlands Heart Registry).20 21 
The process described by Meetbaar Beter consists of the 
following steps: a list of the most important outcomes 
was sent to the expert group and prioritised. A structured 
consensus-driven, RAND-modified Delphi method was 
employed to prioritise the important outcomes anony-
mously on a scale from 0 to 10 (not important to most 
important). The outcomes were ranked on three criteria: 
(1) impact of the outcome on quality of life, (2) impact 
of quality of care on the outcome and (3) the number of 
patients negatively affected by the outcome. Based on the 
total score prioritising the outcomes, four online webinar 
discussions and one face-to-face meeting, final consensus 
on the outcome set was reached. A secondary goal of this 
process was to define a standard set of initial conditions 
required for potential case-mix corrections. This was 
defined based on expert opinion and was ranked accord-
ingly. When differences in prioritisation emerged, they 
were openly discussed until consensus was reached.
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Table 1 Summary of standard set of outcomes for patients with pulmonary sarcoidosis
Outcome set Category Details Timing Data source
1. Mortality Longitudinal
outcomes
Date of death Tracked 
throughout
Administrative
2. Pulmonary function Clinical monitoring 1. FVC% predicted and absolute 
over treatment period
2. FEV1% predicted and absolute 
over treatment period
3. DLCO% predicted and absolute 
over treatment period
Every 3–6 months 
(depending 
on severity of 
sarcoidosis)
Clinical
3. Soluble interleukin-2 
receptor (sIL-2R) change as 
an activity biomarker
Clinical monitoring 1. Date of measurement
2. sIL-2R (measured in pg/mL, limit 
>3000)
Every visit to the 
clinic
Clinical
4. Weight gain Clinical monitoring Weight (kg) measured at each 
pulmonary function test
Every visit to the 
clinic
Clinical
5. Quality of life; physical 
functioning
Patient-reported 
health status
King’s Sarcoidosis Questionnaire40 
and the Fatigue Assessment Scale37
Every 6 months Patient reported
6. Osteoporosis Clinical monitoring Diagnosis T-score
1=Normal >–1.0
2=Osteopenia <–1.0, >–2.5
3=Osteoporosis <–2.5
4=Severe osteoporosis <–2.5 plus 
fragility fractures
5=Not indicated
Based on WHO Osteoporosis 
Classification52
Monitor throughout 
treating the patient
Clinical
7. Clinical outcome status41 Longitudinal
outcomes
1=Resolved never treated
2=Resolved, no therapy >1 year
3=Minimal disease never treated
4=Minimal disease no therapy >1 
year
5=Persistent no current therapy, 
never treated
6=Persistent no current therapy, no 
therapy >1 year
7=Persistent-current therapy, 
asymptomatic
8=Persistent-current therapy, 
symptomatic
9=Persistent-current therapy, 
worsening prior year
99=Unknown
After 2 years and/
or 5 years
Clinician evaluation/
administrative
results
Pulmonary sarcoidosis standard set
The care delivery value chain provides a detailed over-
view of care provided for patients with pulmonary 
sarcoidosis to guide the initial selection of outcome 
measures (see online supplementary material appendix 
2 for a full description). After identifying the most impor-
tant outcomes from the care delivery chain, literature 
and expert opinion, an initial set of 34 outcomes was 
presented to the expert group (see online supplementary 
appendix 4). Next, outcome measures were ranked based 
on the Meetbaar Beter criteria delineated earlier.20 21 Finally, 
the ranking and expert opinion discussions resulted in 
seven outcome measures (table 1) and 10 initial condi-
tions (table 2). Further information how the outcomes 
were prioritised is presented in the online supplementary 
material appendix 4. An overview of data collection and 
its timeline is presented in figure 1.
In the following paragraphs, we discuss our consider-
ations in selecting the seven outcome measures in rela-
tion to the literature. For more detailed information 
concerning the outcome measures, please see online 
supplementary appendix 3 in the online supplement.
tier 1: outcome measures 1, 2 and 3: health status (survival 
and degree of health)
Survival at 1 and 5 years after the diagnosis is an impor-
tant outcome (outcome measure 1), especially for patients 
with advanced pulmonary sarcoidosis. Survival is meas-
ured as all-cause mortality, calculated from clinical and 
administrative data sources. Sarcoidosis-related mortality 
is reported to be up to 7.6% in a US-based population.22 
Most deaths are due to pulmonary fibrosis, pulmonary 
hypertension, neurological and cardiac involvement.9
Outcome measure 2 is pulmonary function (FVC, FEV1 
and DLCOc), which is widely used to monitor disease 
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Table 2 Summary of standard set of initial conditions for patients with pulmonary sarcoidosis
Timing for collection Measure Details Source
First contact with hospital
services
Age Date of birth Administrative
At time of clinical visit Body mass index Weight and height needed Clinical
At time of clinical visit Comorbidity ICD-10+sleep 
apnoea
Documented in history Clinical
First contact with hospital
services
Ethnicity Documented in history Administrative
First contact with hospital
services
Gender Gender at birth
Documented in history
Administrative
At time of clinical visit Multiorgan involvement53 Various clinical manifestations for the 
probability of various sarcoidosis-related 
organ involvement. Ranking options are highly 
probable, at least probable, possible or no 
consensus
Clinical
First contact with hospital
services
Opinion stage (first, 
second, third)
1. First opinion
2. Second opinion
3. Third opinion
Clinical
Stadium X-thorax42 Scadding stage based on 
chest X-ray
1. Stage 0: normal
2. Stage I: lymph nodes in hili or mediastinum
3. Stage II and III: I plus distortion in lung (II)
4. Stage IV: fibrosis in lung, significant fibrotic 
lesions/end-stage disease
Clinician evaluation/
administrative
First contact with hospital
services
Smoking history 1. Never
2. Ever
3. Active (moment of diagnosis an active 
smoker)
Administrative
First contact with hospital
services
Socioeconomic status Postal code Administrative
Figure 1 Example of a timeline when outcomes and baseline factors should be collected for patients with pulmonary 
sarcoidosis. This timeline represents the outcome data collection points for a possible treatment path of a patient with 
pulmonary sarcoidosis. It does not advocate a particular treatment or treatment combination. Patients can receive follow-up 
for up to 5 years, but this can also be longer depending on the disease severity and whether the patient experiences chronic 
pulmonary sarcoidosis. T0=at first physician visit. FAS, Fatigue Assessment Scale; KSQ, King’s Sarcoidosis Questionnaire.
progression. Currently, serial FVC is considered as the 
best endpoint to monitor during the course of care for 
pulmonary sarcoidosis.23
Finally, soluble interleukin-2 receptor (sIL-2R) was 
selected as outcome measure 3. SIL-2R is considered 
to be a marker of T-cell activation.24 A shortcoming of 
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this outcome is the fact that it is not routinely measured 
and implemented in all the collaborating expert clinics. 
Furthermore, there are conflicting data regarding the 
correlation between sIL-2R level changes and respective 
treatment response.25 However, it outperforms conven-
tional biomarkers such as ACE26 and is cheaper and more 
widely available than sensitive tests like fluorodeoxyglu-
cose PET.27
tier 2: outcome measure 4: recovery process (time to 
recovery, disutility of care)
The treatment of pulmonary sarcoidosis aims at 
preventing a progressive disease pattern with organ 
failure. The clinical manifestations are widely variable, 
ranging from asymptomatic radiographic findings to a 
more chronic progressive disease pattern with multiple 
organ failure.28 However, complications due to the treat-
ment of pulmonary sarcoidosis are also significant, such 
as adverse side effects due to high-dose and/or long-term 
prednisone use, excessive weight gain, risk of osteoporosis 
and fatigue.2 29–31 Globally, corticosteroids, such as pred-
nisone, remain the mainstay of therapy in sarcoidosis.9 32 
The initial recommended dose of prednisone is 20–40 
mg/day, which should later be tapered down to a dose 
around or below the 10 mg/day.33 However, it remains 
debated whether prednisone therapy modifies long-term 
progression of the disease.34 We chose weight gain as 
a measure of disutility of care, outcome measure 4 in the 
outcome measures set.
tier 3: outcome measures 5, 6 and 7: sustainability of health 
(ie, sustainability of health of or recovery and long-term 
consequences of therapy)
Health-related quality of life (HRQOL), a key measure 
for patients with pulmonary sarcoidosis, is outcome measure 
5. Fatigue is the most common complaint in patients 
with pulmonary sarcoidosis, reported by 50% to 80% 
of patients.35 36 The process aims to select well-validated 
instruments to address the multidimensional outcome 
domains, minimising the burden for the patients (eg, 
number of questionnaires/questions to fill out) on the 
one hand, while maximising the likelihood of solid longi-
tudinal data collection on the other hand. The Fatigue 
Assessment Scale (FAS) and King’s Sarcoidosis Ques-
tionnaire (KSQ) were selected as the most appropriate 
patient-reported outcome measures in order to monitor 
changes in patients’ quality of life (online supplemen-
tary material appendix 5 and appendix 6). The FAS is 
a well-defined and validated questionnaire in patients 
with sarcoidosis.23 37 The cut-off score for presence of 
fatigue is >21 points.23 The minimal clinical important 
difference is defined at a 10% reduction or a change of 
four points.38 The KSQ is a self-administered measure 
for sarcoidosis covering five different domains of health 
status: (1) general health status, (2) lung, (3) medica-
tion, (4) skin and (5) eyes.39 It consist of 29 questions. 
The KSQ is available in multiple languages.39 40
Patients with pulmonary sarcoidosis are at risk for devel-
oping osteoporosis for a number of reasons, including 
corticosteroid treatment and reduced mobility secondary 
to lung function impairment/musculoskeletal issues or 
other internal organ involvement such as the heart. Data 
on osteoporosis development were therefore included as 
outcome measure 6 of the set.
The WASOG Task Force recommends to score patients 
based on nine predefined criteria, 2 and/or 5 years after 
diagnosis, introduced as the clinical outcome status 
(COS).41 The COS is defined as outcome measure 7 of the set. 
The aim of applying the COS is to standardise the clinical 
outcome description of patients with sarcoidosis and can 
be seen as an important tool for treatment related classi-
fication. For example, patients with persistent disease still 
on therapy at time of repeat evaluation are COS 7, 8 or 9.
Initial conditions
A minimum set of initial conditions to control outcomes 
for differences in patient characteristics was defined. This 
includes characteristics of pulmonary classification on a 
chest radiograph into five stages (Scadding stage).42 Also, 
general patient demographics (age, sex, first, second-
opinion or third-opinion stage, race/ethnicity, body mass 
index, comorbidities) and treatment-related factors are 
included. These initial conditions are associated with the 
disease outcomes (table 2).
The included comorbidities are based on the ICD-10 
codes plus the addition of sleep apnoea (online supple-
mentary appendix 3). This was determined by the 
treating physician and entered into the patient’s medical 
record. For pulmonary sarcoidosis, the ability to iden-
tify black/African-American patients is important, as the 
disease was found to be more severe in black patients.43 
Race/ethnicity documentation however differs by 
country, as well as the means to capture the informa-
tion (self-reported; Caucasian or non-Caucasian vs 
Hispanic or non-Hispanic). For more detailed informa-
tion concerning the initial conditions, please see online 
supplementary appendix 3. The initial conditions were 
extracted from the patient’s administrative and clinical 
data (such as Scadding stage, history of diabetes mellitus 
or sleep apnoea) and were collected when the patient 
visits the clinic for the first time (table 2).
Medication use
In addition to the outcome set and the case-mix variables, 
we also decided to collect information concerning the 
patients’ medication at diagnosis and at the time of each 
visit to the clinic. We aimed to identify the duration and 
variation of first-line, second-line and third-line therapy 
and to allow comparison between centres. In addition, in 
relation to weight changes, the team of experts thought 
medication differences could provide meaningful infor-
mation to better explain weight changes due to pred-
nisone use. Corticosteroid therapy have been reported 
to lead to significant changes in HRQOL.44 Even low 
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doses of prednisone have been associated with significant 
morbidity.30 31 Although this was not part of the outcome 
measures set, consensus was reached to monitor the 
following drugs: corticosteroids, methotrexate, azathio-
prine, non-steroidal anti-inflammatory drugs, infliximab, 
adalimumab, other anti-TNF, leflunomide, inhalation 
therapy, other systematic therapy for (extra)pulmonary 
sarcoidosis and hydroxychloroquine.
DIscussIon
A first outcome measure set was developed for patients 
with pulmonary sarcoidosis consisting of seven outcome 
measures: mortality (1 and 5 years), pulmonary func-
tion (FEV1, FVC, DLCOc), sIL-2R change as an activity 
biomarker, weight gain, quality of life, osteoporosis and 
clinical outcome status. Routine data collection based on 
standardised outcome measures creates an opportunity 
to improve patient care. A reliable data collection process 
for patients with pulmonary sarcoidosis enables us to 
compare outcomes between various clinics/treatments, 
which can ultimately help to identify best practices.
The international consensus process resulted in a set 
of patient-centred outcomes with case-mix variables. 
This can enable clinicians to measure and benchmark 
outcomes. It is, however, important to note that the set 
presented in our paper should not limit any inclusion of 
additional treatment and/or process-related outcomes 
supporting quality improvement efforts. It is expected 
that in efforts to create a multicentre registry, centres 
will continue to collect additional data, such as the initial 
dose of prednisone, the rate of prednisone tapering and 
the timing of a potential switch to second-line therapy 
(such as methotrexate or azathioprine).
This outcome measures set could be used on a monthly 
or yearly basis in order to benchmark outcomes. More-
over, this set can be used to compare the quality of 
care delivered by different centres around the world, 
which in turn can trigger discussion and define future 
learning potential for other clinics treating this patient 
group. Second, it could be used to assess best practices 
in a field where there is a scarcity on evidence-based 
therapies. Other initiatives have developed classification 
protocols, although this is more based on clinical criteria 
as a tool for studies evaluating disease mechanisms in 
patients with sarcoidosis to be correlated with clinical 
outcomes.45 For example, the GRADS initiative aims to 
compare blood genomics with clinical phenotypic vari-
ables and assess each participant’s clinical course during 
follow-up.46 This recommended outcome measures set is 
a first step at applying a global standard. Future experi-
ences in comparing outcomes using the set are needed to 
further refine the global standard set.
Ultimately, healthcare-related patient value should be 
defined as value achieved from the perspective of the 
patient and their respective changes in most important 
clinical outcomes relative to its costs.8 This includes 
perceived health status, QoL as well the impact of choices 
made during treatment, for example, weight gain as a 
side effect due to prednisone. The establishment of an 
international global standard to collect and compare 
outcomes for patients with pulmonary sarcoidosis will 
enable more systematic follow-up of the patients’ quality 
of life.
In order to support further progress to measure and 
transparently compare outcomes for pulmonary sarcoid-
osis, investments should be made in a longitudinal-ori-
ented registry. This will result in a more structured 
process when collecting this type of outcome data. In 
addition, improving the data infrastructure and relying 
on less manual data entry can improve the validity of the 
data.
The ultimate goal when reporting clinical outcomes 
is to inform patients, clinicians and managers with 
credible performance data.47 Additionally, improved 
documentation, open communication, encouraging 
quality improvement and increasing informed deci-
sion-making for patients are of great importance when 
reporting and comparing outcomes.48 Making use of a 
clinical registry and reporting outcome data through, 
for example, annual reports to the public can promote 
quality improvements in healthcare, reduce potential 
variations in the quality of care delivered and improve 
data validity.49 50
The set was developed by physicians, as there was 
a strong need for standardisation from the medical 
specialties. Annual maintenance cycles in order to eval-
uate the set should be considered important to contin-
uously improve the set, as suggested by others.21 These 
cycles can be used to generate new scientific input to 
re-evaluate the outcome measures incorporated in the 
set.
The interdisciplinary character can be improved (eg, 
include radiologist and psychologist in the expert group 
during maintenance cycles). Also, five out of the 14 
expert group members were affiliated with the St. Anto-
nius Hospital. This was due to the fact that this centre 
initiated the study. Although this can create potential 
bias, during the webinars consensus was reached among 
all expert group members. In addition, it is necessary 
to discuss and validate the set with patients and possibly 
further improve the set using their perspectives as we did 
not include patient perspectives in the generation of the 
consensus. In a recent study (in press), survey findings 
showed that patients (n=1842) want quality of life and 
functionality to be included as outcomes in their treat-
ment.51 In this study, patients from different counties 
were included (692 Dutch, 528 German, 338 English, 148 
Italian, 107 Spanish, 29 French). Finally, for the devel-
opment of this set, we had an international group with 
experts from different centres, but not all continents were 
represented. Future efforts on updating the outcome set 
should put more efforts on a larger global coverage and 
collaboration between different centres treating patients 
with pulmonary sarcoidosis.
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conclusIons
The international process resulted in a consensus-driven 
recommended first set of patient-centred outcomes 
in patients with a diagnosis of pulmonary sarcoidosis. 
Applying this outcome set has the potential to better 
inform patients, healthcare providers and other stake-
holders in achieving value-based care for patients with 
pulmonary sarcoidosis. The full potential of applying 
VBHC principles in pulmonary sarcoidosis is however yet 
to be explored.
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